Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
334M
-
Number of holders
-
225
-
Total 13F shares, excl. options
-
160M
-
Shares change
-
+5.22M
-
Total reported value, excl. options
-
$4.15B
-
Value change
-
+$95M
-
Put/Call ratio
-
0.39
-
Number of buys
-
137
-
Number of sells
-
-111
-
Price
-
$26.02
Significant Holders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) as of Q2 2021
317 filings reported holding IOVA - IOVANCE BIOTHERAPEUTICS, INC. - Common Stock as of Q2 2021.
IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) has 225 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 160M shares
of 334M outstanding shares and own 47.75% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (18.5M shares), VANGUARD GROUP INC (12.2M shares), PERCEPTIVE ADVISORS LLC (11M shares), Avoro Capital Advisors LLC (9.1M shares), Sumitomo Mitsui Trust Holdings, Inc. (7.74M shares), Nikko Asset Management Americas, Inc. (7.72M shares), WELLINGTON MANAGEMENT GROUP LLP (7.25M shares), FRANKLIN RESOURCES INC (7.23M shares), BlackRock Inc. (6.77M shares), and ORBIMED ADVISORS LLC (6.65M shares).
This table shows the top 225 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.